NO955314L - Immunoanalyser for opplöselige fibrinpolymerer - Google Patents
Immunoanalyser for opplöselige fibrinpolymererInfo
- Publication number
- NO955314L NO955314L NO955314A NO955314A NO955314L NO 955314 L NO955314 L NO 955314L NO 955314 A NO955314 A NO 955314A NO 955314 A NO955314 A NO 955314A NO 955314 L NO955314 L NO 955314L
- Authority
- NO
- Norway
- Prior art keywords
- immunoassays
- fibrin polymers
- bacilli
- immunized
- vitro
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/972—Modified antibody, e.g. hybrid, bifunctional
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En fremgangsmåte for produksjon av monoklonale antistoffer er beskrevet. Fremgangsmåten anvender et immunisert basillfritt dyr. Det er også beskrevet fremgangsmåter for anvendelse av slike monoklonale antistoffer, og polyklonale antistoffer avledet fra et immunisert basillfritt dyr, for in vitro og in vivo klinisk diagnostikk og terapi. Et fibrinspesifikt monoklonalt antistoffer også beskrevet. Det er også beskrevet in vitro fremgangsmåter for deteksjon av fibrinogennivåer i plasmaprøver, for deteksjon av oppløselige kryssbundede og ikke kryssbundede fibrinpolymerer i pattedyrprøver.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/086,423 US5453359A (en) | 1988-06-13 | 1993-07-02 | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
PCT/US1994/007087 WO1995001568A1 (en) | 1993-07-02 | 1994-06-22 | Immunoassay for soluble fibrin polymers |
Publications (2)
Publication Number | Publication Date |
---|---|
NO955314D0 NO955314D0 (no) | 1995-12-27 |
NO955314L true NO955314L (no) | 1996-02-20 |
Family
ID=22198474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO955314A NO955314L (no) | 1993-07-02 | 1995-12-27 | Immunoanalyser for opplöselige fibrinpolymerer |
Country Status (18)
Country | Link |
---|---|
US (7) | US5453359A (no) |
EP (1) | EP0706656A4 (no) |
JP (1) | JPH08512136A (no) |
KR (1) | KR100291368B1 (no) |
CN (1) | CN1129984A (no) |
AU (1) | AU688345B2 (no) |
BR (1) | BR9406944A (no) |
CA (1) | CA2166386A1 (no) |
CZ (1) | CZ696A3 (no) |
FI (1) | FI960006A (no) |
HU (1) | HUT73804A (no) |
NO (1) | NO955314L (no) |
NZ (1) | NZ268785A (no) |
PL (1) | PL178003B1 (no) |
RU (1) | RU2173347C2 (no) |
SG (1) | SG50674A1 (no) |
SK (1) | SK596A3 (no) |
WO (1) | WO1995001568A1 (no) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
ATE385506T1 (de) * | 1993-11-02 | 2008-02-15 | Mitsubishi Kagaku Iatron Inc | Antikörper gegen menschliches lösliches fibrin, hybridome, die sie produzieren und immunmessverfahren |
CA2188647A1 (en) * | 1994-05-02 | 1995-11-09 | Stewart Anthony Cederholm-Williams | Recombinant fibrin chains, fibrin and fibrin-homologs |
US6991907B1 (en) * | 1995-04-18 | 2006-01-31 | Biosite, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
US6627404B1 (en) * | 1995-04-18 | 2003-09-30 | Biosite, Inc. | Methods for improving the recovery of troponin I and T in membranes, filters and vessels |
AU6025496A (en) * | 1995-06-07 | 1996-12-30 | American Biogenetic Sciences, Inc. | Calibrator for use in a soluble fibrin assay |
US5817768A (en) * | 1995-06-07 | 1998-10-06 | The New York Blood Center, Inc. | Monospecific antibodies against a subunit of fibrinogen |
JP3742675B2 (ja) * | 1995-06-28 | 2006-02-08 | 東菱薬品工業株式会社 | 虚血−再灌流障害の予防および治療薬 |
AU6398596A (en) * | 1995-06-30 | 1997-02-05 | American Biogenetic Sciences, Inc. | Method of producing fibrin-specific antibodies using soluble fibrin polymers as an immunogen |
US6962981B1 (en) * | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US7381407B1 (en) * | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
WO1997037755A1 (en) * | 1996-04-09 | 1997-10-16 | Sarnoff Corporation | Plate for reaction system |
US5840256A (en) * | 1996-04-09 | 1998-11-24 | David Sarnoff Research Center Inc. | Plate for reaction system |
US5938595A (en) * | 1996-05-24 | 1999-08-17 | The Regents Of The University Of California | Fiber optic D dimer biosensor |
KR100222292B1 (ko) * | 1997-06-18 | 1999-10-01 | 허일섭 | 피브린 단량체를 이용한 혈액 응고 제 13인자의활성 측정방법 |
US6727102B1 (en) | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
WO1998059047A1 (fr) * | 1997-06-24 | 1998-12-30 | Nissui Pharmaceutical Co., Ltd. | Anticorps monoclonal specifique d'un monomere anti fibrine humaine, son procede d'obtention, hybridomes et procedes relatifs a des immuno-essais |
JP2002517223A (ja) | 1998-06-12 | 2002-06-18 | ジェネンテック・インコーポレーテッド | モノクローナル抗体、交叉反応性抗体およびそれを生成する方法 |
US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
CA2390261C (en) | 1999-11-08 | 2014-04-22 | University Of Florida Research Foundation, Inc. | Marker detection method and apparatus to monitor drug compliance |
FR2813395B1 (fr) * | 2000-08-28 | 2003-01-24 | Stago Diagnostica | Methode de dosage in vitro de la fibrine soluble par generation de produits de degradation specifiques |
US20020043389A1 (en) * | 2000-09-29 | 2002-04-18 | Selvarajan Murugan | Virtual gate design for thin packages |
US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
US7104963B2 (en) * | 2002-01-22 | 2006-09-12 | University Of Florida Research Foundation, Inc. | Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath |
US6981947B2 (en) * | 2002-01-22 | 2006-01-03 | University Of Florida Research Foundation, Inc. | Method and apparatus for monitoring respiratory gases during anesthesia |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US20040176914A1 (en) * | 2001-04-13 | 2004-09-09 | Biosite Incorporated | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040121350A1 (en) * | 2002-12-24 | 2004-06-24 | Biosite Incorporated | System and method for identifying a panel of indicators |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
ATE439588T1 (de) | 2001-05-04 | 2009-08-15 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
US7052854B2 (en) | 2001-05-23 | 2006-05-30 | University Of Florida Research Foundation, Inc. | Application of nanotechnology and sensor technologies for ex-vivo diagnostics |
EP1393069A1 (en) | 2001-05-24 | 2004-03-03 | The University Of Florida | Method and apparatus for detecting environmental smoke exposure |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20070167853A1 (en) | 2002-01-22 | 2007-07-19 | Melker Richard J | System and method for monitoring health using exhaled breath |
WO2003072061A2 (en) * | 2002-02-26 | 2003-09-04 | Sangstat Medical Corporation | Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
EP1673465A4 (en) * | 2003-09-29 | 2008-04-30 | Biosite Inc | PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS |
US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
US20080050832A1 (en) * | 2004-12-23 | 2008-02-28 | Buechler Kenneth F | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
JP4088328B2 (ja) * | 2004-12-28 | 2008-05-21 | 第一化学薬品株式会社 | 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法 |
NZ560414A (en) * | 2005-02-18 | 2011-04-29 | Medarex Inc | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
WO2007103568A2 (en) * | 2006-03-09 | 2007-09-13 | Biosite, Inc. | Methods and compositions for the diagnosis of diseases of the aorta |
US20080118924A1 (en) * | 2006-05-26 | 2008-05-22 | Buechler Kenneth F | Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
EP1870712A1 (en) * | 2006-06-20 | 2007-12-26 | Universität Bern | Method for assaying a thrombotic event |
US7914460B2 (en) | 2006-08-15 | 2011-03-29 | University Of Florida Research Foundation, Inc. | Condensate glucose analyzer |
US7740801B2 (en) * | 2006-10-31 | 2010-06-22 | Lifescan Scotland Limited | System for determination of an analyte in a bodily fluid sample that includes an electroluminescent component |
EP2095106B1 (en) * | 2006-11-14 | 2013-03-20 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
EP2500723B1 (en) | 2006-11-14 | 2015-07-08 | Alere San Diego, Inc. | Methods for monitoring and risk prediction in cardiorenal syndrome |
US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US8221995B2 (en) * | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US20140350129A1 (en) * | 2011-09-07 | 2014-11-27 | Genway Biotech, Inc. | Diagnostic assay to predict cardiovascular risk |
US9754505B2 (en) | 2012-03-29 | 2017-09-05 | F. Hoffmann-La Roche Ag | Method for training staff in quality control |
CN104205131A (zh) * | 2012-03-29 | 2014-12-10 | 霍夫曼-拉罗奇有限公司 | 用于在质量控制中对人员进行培训的方法 |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
BR112015013444B1 (pt) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
CN103954758A (zh) * | 2014-05-15 | 2014-07-30 | 海南世济医学技术有限公司 | 一种用于纤维蛋白和纤维蛋白原及其降解产物的检测方法和试剂盒 |
CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
WO2020092531A1 (en) * | 2018-10-30 | 2020-05-07 | The Research Institute At Nationwide Children's Hospital | Factor xiii immunoassay |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1362776A (en) * | 1970-07-17 | 1974-08-07 | Wellcome Found | Immunological reagent |
DE2532151C3 (de) * | 1975-07-18 | 1979-06-13 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Antisenim zur quantitativen Bestimmung der Abbauprodukte des Fibrins und Fibrinogen« und Verfahren zu seiner Herstellung |
US4036945A (en) * | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
US4355023A (en) * | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
US4438209A (en) * | 1981-07-17 | 1984-03-20 | Mallinckrodt, Inc. | Radioimmunoassay for fibrinopeptide A |
US4550086A (en) * | 1983-02-16 | 1985-10-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that recognize human T cells |
AU572125B2 (en) * | 1983-03-17 | 1988-05-05 | Mabco Limited | Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses |
US4722903A (en) * | 1983-11-14 | 1988-02-02 | New York Blood Center, Inc. | Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II |
US4927916A (en) * | 1984-04-23 | 1990-05-22 | The General Hospital Corporation | Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides |
US5256413A (en) * | 1985-01-08 | 1993-10-26 | The General Hospital Corporation | Method and use for site-specific activation of substances |
AU595173B2 (en) * | 1985-01-08 | 1990-03-29 | General Hospital Corporation, The | Method and use for site-specific activation of substances |
NL8501682A (nl) * | 1985-06-11 | 1987-01-02 | Tno | Nieuw, uit bloed geisoleerd eiwit, werkwijze ter bereiding van dit eiwit, antilichamen tegen het nieuwe eiwit en farmaceutische preparaten, die het eiwit of de antilichamen bevatten. |
US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
US5120834A (en) * | 1988-06-13 | 1992-06-09 | American Biogenetic Sciences, Inc. | Fibrin-specific monoclonal antibody |
US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
US5091512A (en) * | 1988-06-13 | 1992-02-25 | American Biogenetic Sciences, Inc. | Fibrinogen-specific monoclonal antibody |
US5223410A (en) * | 1988-06-13 | 1993-06-29 | American Biogenetic Sciences, Inc. | Method for production of antibodies utilizing an antigen-free animal |
IE67430B1 (en) * | 1988-06-24 | 1996-04-03 | Res Corp Technologies Inc | Assay for soluble crosslinked fibrin polymers |
US5487892A (en) * | 1994-02-24 | 1996-01-30 | American Biogenetic Sciences, Inc. | Method for treating thrombotic disease using a fibrin specific monoclonal antibody |
-
1993
- 1993-07-02 US US08/086,423 patent/US5453359A/en not_active Expired - Lifetime
-
1994
- 1994-06-22 SK SK5-96A patent/SK596A3/sk unknown
- 1994-06-22 JP JP7503560A patent/JPH08512136A/ja active Pending
- 1994-06-22 HU HU9503875A patent/HUT73804A/hu unknown
- 1994-06-22 BR BR9406944A patent/BR9406944A/pt not_active Application Discontinuation
- 1994-06-22 CA CA002166386A patent/CA2166386A1/en not_active Abandoned
- 1994-06-22 AU AU72122/94A patent/AU688345B2/en not_active Ceased
- 1994-06-22 CZ CZ966A patent/CZ696A3/cs unknown
- 1994-06-22 SG SG1996008390A patent/SG50674A1/en unknown
- 1994-06-22 WO PCT/US1994/007087 patent/WO1995001568A1/en not_active Application Discontinuation
- 1994-06-22 RU RU96103363/13A patent/RU2173347C2/ru not_active IP Right Cessation
- 1994-06-22 CN CN94193177A patent/CN1129984A/zh active Pending
- 1994-06-22 EP EP94921364A patent/EP0706656A4/en not_active Withdrawn
- 1994-06-22 KR KR1019950705946A patent/KR100291368B1/ko not_active IP Right Cessation
- 1994-06-22 NZ NZ268785A patent/NZ268785A/en unknown
- 1994-06-22 PL PL94312384A patent/PL178003B1/pl unknown
-
1995
- 1995-06-02 US US08/459,596 patent/US5843690A/en not_active Expired - Lifetime
- 1995-06-02 US US08/460,702 patent/US5723126A/en not_active Expired - Lifetime
- 1995-06-02 US US08/460,698 patent/US5721122A/en not_active Expired - Lifetime
- 1995-12-27 NO NO955314A patent/NO955314L/no not_active Application Discontinuation
-
1996
- 1996-01-02 FI FI960006A patent/FI960006A/fi unknown
-
1998
- 1998-03-19 US US09/044,063 patent/US5871737A/en not_active Expired - Fee Related
- 1998-12-09 US US09/207,913 patent/US6187593B1/en not_active Expired - Fee Related
-
2000
- 2000-11-28 US US09/724,404 patent/US6294173B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5453359A (en) | 1995-09-26 |
AU7212294A (en) | 1995-01-24 |
US5871737A (en) | 1999-02-16 |
SK596A3 (en) | 1996-05-08 |
AU688345B2 (en) | 1998-03-12 |
KR100291368B1 (ko) | 2002-02-01 |
HUT73804A (en) | 1996-09-30 |
US6294173B1 (en) | 2001-09-25 |
CA2166386A1 (en) | 1995-01-12 |
FI960006A (fi) | 1996-03-01 |
WO1995001568A1 (en) | 1995-01-12 |
CZ696A3 (en) | 1996-07-17 |
PL178003B1 (pl) | 2000-02-29 |
US6187593B1 (en) | 2001-02-13 |
JPH08512136A (ja) | 1996-12-17 |
HU9503875D0 (en) | 1996-02-28 |
CN1129984A (zh) | 1996-08-28 |
EP0706656A1 (en) | 1996-04-17 |
RU2173347C2 (ru) | 2001-09-10 |
US5721122A (en) | 1998-02-24 |
NZ268785A (en) | 1997-12-19 |
US5723126A (en) | 1998-03-03 |
FI960006A0 (fi) | 1996-01-02 |
US5843690A (en) | 1998-12-01 |
EP0706656A4 (en) | 1998-05-20 |
PL312384A1 (en) | 1996-04-15 |
BR9406944A (pt) | 1996-08-06 |
NO955314D0 (no) | 1995-12-27 |
SG50674A1 (en) | 1998-07-20 |
KR960703468A (ko) | 1996-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO955314L (no) | Immunoanalyser for opplöselige fibrinpolymerer | |
AU2097692A (en) | Method for the production of monoclonal antibodies utilizing a germfree animal | |
NO841023L (no) | Monoklonale antistoff som er spesifikke overfor tverrbundne fibrinderivater, og fremgangsmaate for paavisning av disse derivater | |
MY108526A (en) | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same | |
AU6943896A (en) | Antibody againts alpha-chain of human interleukin 5 receptor | |
DE69128273D1 (de) | Für toxin b von clostridium difficile spezifische monoklonale antikörper | |
DK0678524T3 (da) | Antistoffer mod oplöselig human fibrin, hybridom, der producerer dem, samt immunassayfremgangsmåde | |
GR3031607T3 (en) | Selective system scan for multizone radiotelephone subscriber units. | |
KR900702008A (ko) | 무균동물을 이용하는 단일클론의 항체의 제조방법 | |
DE69619416D1 (de) | Verfahren und Reagenzien zum immunologischen Nachweis von Cortisol im Urin | |
ATE229037T1 (de) | Monoklonaler antikörper gegen denthrombin- antithrombin iii-komplex und dessen verwendung in immunoassays | |
AU4086397A (en) | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen | |
GR3018780T3 (en) | Monoclonal antibody recognizing membrane phospholipase A2 and immunoassay of membrane phospholipase A2. | |
DK329789D0 (da) | Monoklonalt antistof | |
JPH0611507A (ja) | ヒトポドカリキシンの測定方法 | |
EP0334076A3 (en) | Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same | |
DK0519536T3 (da) | Diagnostisk fremgangsmåde | |
EP0338497A3 (en) | Bispecific hybrid monoclonal antibody | |
AU6162794A (en) | Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor | |
DK0574461T3 (da) | Humaniserede, monoklonale højaffinitetsantistoffer | |
ES2067387A1 (es) | Procedimiento para la caracterizacion de antigenos mediante el uso cuantitativo de anticuerpos monoclonales. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |